SOUTH SAN FRANCISCO, CA – May 14, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity to the patient, today announced that the first clinical data from the phase 1 study to evaluate its lead therapeutic candidate, AMV564, alone and in combination with pembrolizumab, in subjects with advanced solid tumors, will be presented in a virtual poster presentation as part of the ASCO Annual Meeting (Virtual Format May 29 – June 2, 2020).
The Phase 1 clinical study (NCT04128423) in patients with advanced solid tumor malignancies was designed to assess the safety, PK, pharmacodynamic response and preliminary efficacy of escalating doses of AMV564 administered once daily via subcutaneous injection, alone or in combination with pembrolizumab for 2 weeks out of every 3 week cycle.
Details of the Presentation:
Title: A Phase 1 Study to Evaluate the T-cell Engager AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Authors: Starodub, A. et al.
Abstract Number: 3101 (Poster: 165)
Poster Viewing: Available on demand beginning May 29 at 8:00 AM ET
The full abstract is available now and poster will be available on May 29th on the ASCO Annual Meeting and Amphivena websites.
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company’s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. AMV564 has an excellent safety profile that enables competitive approaches, including subcutaneous drug delivery, combination therapy, and provides a unique opportunity to bring new treatment options for cancer patients underserved by immunotherapy.
Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC.